lonquex
teva b.v. - lipegfilgrastim - daufkyrningafæð - Ónæmisörvandi, , nýlendan að örva þáttum - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients með ört vaxandi alvarlega köstum skil heila-og mænusigg skilgreind af 2 eða meira að slökkva köst í eitt ár, og með 1 eða meira skuggaefna efla sár á heilanum segulÓmun eða mikil aukning í t2 sár álag eins og miðað við fyrri undanförnum segulÓmun.
fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
palladia
zoetis belgium sa - toceranib - Æxlishemjandi lyf - hundar - meðferð við lifrarfrumukrabbamein í hundum sem ekki eru tilbúnir til endurtekninga (ii).
trocoxil
zoetis belgium sa - mavacoxib - bólgueyðandi og verkjalyf vörur - hundar - til meðhöndlunar á verkjum og bólgu sem tengist þvagræsilissjúkdómum hjá hundum þar sem stöðugur meðferð yfir einn mánuð er tilgreindur.
aromasin húðuð tafla 25 mg
pfizer aps - exemestanum inn - húðuð tafla - 25 mg
detrusitol retard hart forðahylki 2 mg
upjohn eesv - tolterodinum l-tartrat - hart forðahylki - 2 mg
detrusitol retard hart forðahylki 4 mg
upjohn eesv - tolterodinum l-tartrat - hart forðahylki - 4 mg
dostinex tafla 0,5 mg
pfizer aps - cabergolinum inn - tafla - 0,5 mg
relpax filmuhúðuð tafla 40 mg
upjohn eesv - eletriptanum brómíð - filmuhúðuð tafla - 40 mg